1. Biochemical Assay Reagents
  2. SBE-β-CD

SBE-β-CD (Synonyms: Sulfobutylether-β-Cyclodextrin)

Cat. No.: HY-17031 Purity: >98.0%
Handling Instructions

SBE-β-CD est un dérivé de sulfobutyléther β-cyclodextrine utilisé comme excipient ou agent de formulation pour augmenter la solubilité d'agents peu solubles.

SBE-β-CD ist ein Sulfobutylether-β-Cyclodextrinderivat, das als Hilfsstoff oder Formulierungsmittel zur Erhöhung der Löslichkeit schwerlöslicher Mittel verwendet wird.

SBE-β-CD is a sulfobutylether β-cyclodextrin derivative used as an excipient or a formulating agent to increase the solubility of poorly soluble agents.

For research use only. We do not sell to patients.

SBE-β-CD Chemical Structure

SBE-β-CD Chemical Structure

CAS No. : 182410-00-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
500 mg USD 50 In-stock
Estimated Time of Arrival: December 31
1 g USD 96 In-stock
Estimated Time of Arrival: December 31
5 g USD 198 In-stock
Estimated Time of Arrival: December 31
10 g USD 300 In-stock
Estimated Time of Arrival: December 31
25 g USD 600 In-stock
Estimated Time of Arrival: December 31
50 g USD 1080 In-stock
Estimated Time of Arrival: December 31
> 100 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 25 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

SBE-β-CD is a sulfobutylether β-cyclodextrin derivative used as an excipient or a formulating agent to increase the solubility of poorly soluble agents[1].

In Vitro

SBE-β-CD is a chemically modified β-CD that is a cyclic hydrophilic oligosaccharide which is negatively charged in aqueous media. β-CD functioned is a solubilizer only at low concentrations, whereas SBE7-β-CD exhibits strong solubilizing effects over a wide concentration range[1].

In Vivo

20% SBE-β-CD in saline:
Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs).
1. Dissolve 0.9 g of NaCl in 100 mL distilled water to make a clear 0.9% saline solution.
2. Measure 2 g of dry SBE-β-CD.
3. Dissolve 2 g of SBE-β-CD in 10 mL 0.9% saline to make a 20% (w/v) solution. These may require ultrasonic (20-40 kHz, 30 seconds, repeat 3 times) or heating (37°C for about 30 minutes). If precipitation is observed, the precipitates can be dissolved by heating to 37°C and vortexing before use.

CAS No.

182410-00-0

SMILES

[R]O[[email protected]@H]1[[email protected]](O[R])[[email protected]](O[[email protected]@H]2[[email protected]](O[R])C(O[R])[[email protected]](O3)[[email protected]@H](CO[R])O2)[[email protected]@H](CO[R])O[[email protected]@H]1O[[email protected]]4[[email protected]](O[R])[[email protected]@H](O[R])[[email protected]@H](O[[email protected]]5[[email protected]](O[R])[[email protected]@H](O[R])[[email protected]@H](O[[email protected]@H]6C(O[R])[[email protected]](O[R])[[email protected]](O[[email protected]@H]7[[email protected]@H](O[R])[[email protected]](O[R])[[email protected]](O[[email protected]@H]8[[email protected]@H](O[R])[[email protected]](O[R])[[email protected]]3O[[email protected]]8CO[R])O[[email protected]]7CO[R])O[[email protected]]6CO[R])O[[email protected]@H]5CO[R])O[[email protected]@H]4CO[R].[R= H 21-m or C4H8SO3-Na+ m , m=6.0-7.1]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : protect from light

References
Animal Administration
[2]

Rats[2]
A 300 g rat is administered with 1 mL of a 0.1 M SBE-β-CD solution containing 5.64 mg of Compound 1, and assuming an extracellular volume of 90 mL, less than 0.1% of the complex would rapidly dissociate due to the initial effects of dilution. This calculation, combined with the changing blood to plasma ratio in the presence of SBE-β-CD, provides a reasonable explanation for the observed differences in the blood and plasma profiles of Compound 1 after intravenous administration in either the cyclodextrin or cyclodextrin-free formulations. After IV administration of the cyclodextrin formulation, Compound 1 would initially be prevented from distributing into erythrocytes thereby resulting in a whole blood to plasma ratio of less than one. Subsequently, clearance of SBE-β-CD from the circulation would lead to changes in the complexation equilibrium such that the unbound fraction of Compound 1 would increase, thereby reestablishing normal blood to plasma partitioning (i.e. in favour of whole blood) and clearance.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

Purity: >98.0%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

SBE-β-CDSulfobutylether-β-CyclodextrinOthersInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SBE-β-CD
Cat. No.:
HY-17031
Quantity:
MCE Japan Authorized Agent: